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Strengths and limitations of this study
 ► Multicentre prospective cohort study which will 
generate high- quality data to support the safety of a 
novel approach to implant- based breast reconstruc-
tion prior to undertaking a definitive randomised 
controlled trial (RCT).
 ► The study will assess the feasibility of using an inno-
vative mixed- methods approach to promote shared 
surgical learning and establish when a novel surgi-
cal intervention is sufficiently stable for evaluation in 
the context of an RCT.
 ► The Pre- BRA (BRA, breast reconstruction evalua-
tion) study is a single- arm study without an in- built 
comparison group but the results will be compared 
safety data from recently published iBRA study and 
national quality standards.
 ► The feasibility of using mixed- methods to share 
learning and determine when the procedure has 
stabilised will depend on surgeon engagement, and 
the feasibility of this approach is yet to be explored.
ABSTRACT
Introduction Implant- based breast reconstruction is 
the most commonly performed reconstructive technique 
worldwide. Subpectoral reconstruction with mesh is the 
current standard of care but new prepectoral techniques 
have recently been introduced. Prepectoral breast 
reconstruction (PPBR) may improve outcomes for patients 
but robust evaluation is required. Randomised clinical 
trials (RCTs) are ideally needed but the short- term safety 
of PPBR is yet to be established; the technique and its 
indications are evolving and it has yet to be adopted by a 
sufficient number of surgeons for an RCT to be feasible.
The Pre- BRA study aims to determine the feasibility of 
using mixed- methods within an IDEAL 2a/2b (IDEAL, Idea- 
Development- Exploration- Assessment- Long- term) study 
to explore the short- term safety of PPBR and determine 
when the technique is sufficiently stable for evaluation in a 
pragmatic RCT.
Methods and analysis Pre- BRA is an IDEAL stage 2a/2b 
prospective multicentre cohort study with embedded 
qualitative research.
Consecutive patients electing to undergo immediate 
PPBR at participating centres will be invited to participate. 
Demographic, operative, oncology and complication data 
will be collected and patient- reported outcomes will be 
assessed at baseline, 3 and 18 months postoperatively. 
The primary safety endpoint will be implant loss at 3 
months.
Surgeons performing PPBR will be asked to complete 
questionnaires regarding their practice and report any 
modifications made to the procedure or learning arising 
from complications via free- text response fields on 
electronic case- report forms. Semistructured will explore 
surgeons’ experiences in detail to identify emerging best 
practice. This will be fed back to participating surgeons to 
promote shared learning.
The Pre- BRA study will aim to recruit 341 patients from 30 
to 40 UK centres over a 12- month period. Recruitment will 
commence Spring 2019.
Ethics and dissemination The study has full ethical 
approval from OXFORD- B South Central Committee 
Ref:19/SC/0129. Results will be presented at national and 
international meetings and published in peer- reviewed 
journals.
Trial registration number ISRCTN11898000; Pre- results.
InTRoduCTIon
Up to 40%1 of the 55 0002 women diagnosed 
with breast cancer each year in the UK will 
require a mastectomy and of these, approx-
imately one in four will elect to have an 
immediate breast reconstruction3 to improve 
their quality of life.4 Implant- based breast 
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reconstruction (IBBR) is the most commonly performed 
technique worldwide5 6 and subpectoral implant- based 
breast reconstruction with biological or synthetic mesh 
has become the standard of care despite the lack of high- 
quality data to support the safety or effectiveness of the 
technique.7 8
Recently, however, mesh- based techniques have evolved 
further with early studies9 suggesting good results when 
fixed- volume implants are completely covered in a biolog-
ical10–12 or synthetic mesh13–16 and placed on top of the 
muscle in a prepectoral position. This ‘muscle- sparing’ 
technique may result in less postoperative pain, more 
natural results and may prevent ‘implant animation’, the 
upwards movement of the implant seen when the pectoral 
muscle contracts.17
While early results18 of this prepectoral technique are 
promising in the hands of a few expert surgeons,10 11 13–15 19 20 
historically subcutaneous implant placement without mesh, 
was abandoned by the reconstructive community due to 
high complication rates.21–24 To date, few well- designed 
prospective studies have directly compared prepectoral and 
subpectoral IBBR techniques,25 and evidence to support 
the proposed benefits of prepectoral implant placement 
is inconsistent.17 26 27 There is therefore a need to robustly 
evaluate prepectoral implant reconstruction (PPBR) before 
it becomes standard practice.18 Randomised clinical trials 
(RCTs) provide the best evidence, but the safety of prepec-
toral breast reconstruction has yet to be established; the 
technique and its indications are still evolving, and it has 
not yet been adopted by a sufficient number of surgeons 
in the UK for a randomised trial to be feasible. Preliminary 
work is therefore needed before definitive evaluation can 
be considered.
The IDEAL (Idea- Development- Exploration- Assessment- 
Long- term Study) Framework provides recommendations 
for the evaluation of a surgical innovation from first- in- man 
to long- term study.28 29 Phases 2a (Development)/2b (Explo-
ration) focus on feasibility work for a definitive future trial 
including establishing the risks and benefits of the tech-
nique; the stability of the intervention, its indications and 
the adoption of the procedure by a wider group of surgeons 
from the initial innovators.30 While the scope and intention 
of IDEAL is clearly defined, the system is not well opera-
tionalised, and methods for the optimal conduct of early- 
phase surgical studies are unclear. Embedding qualitative 
methods within an IDEAL study may provide a novel way of 
enhancing shared learning within the surgical community 
to reduce learning curve effects and allow a new procedure 
to be introduced more safely and efficiently. Monitoring 
and sharing modifications may also provide an effective way 
of determining when the procedure is sufficiently stable for 
formal evaluation in the context of a definitive RCT.
METhodS And AnAlySIS
Primary aim
The aim of Pre- BRA is to determine the feasibility of using 
mixed- methods within an IDEAL 2a/2b study to explore 
the short- term safety and effectiveness of PPBR and deter-
mine when it is sufficiently stable for formal evaluation in 
a definitive RCT.
Specific objectives
1. To establish the short- term safety (implant loss; in-
fection; reoperation and readmission at 3 months) 
and effectiveness (patient- reported outcomes using 
BREAST- Q at 3 and 18 months) of PPBR compared 
with published national standards from the National 
Mastectomy and Breast Reconstruction Audit31 and 
iBRA7 studies.
2. To explore the feasibility of using a novel mixed- 
methods approach in an IDEAL 2a/2b study to pro-
mote shared learning and identify intervention stabil-
ity including the acceptability of the methodology to 
surgeons and the most effective methods for providing 
feedback.
3. To inform the feasibility, design and conduct of a fu-
ture RCT including the numbers of patients at partic-
ipating centres undergoing IBBR who are eligible for 
PPBR; types of meshes used and approach to concom-
itant interventions.
4. To build capacity to deliver a future RCT by establish-
ing a network of surgeons engaged in the need for 
evaluation who are able to perform PPBR to a high 
standard and who will participate in a future study.
Study design
The Pre- BRA study is a multicentre, IDEAL phase 2a/2b 
prospective observational cohort study with embedded 
qualitative methods.
Patient and public involvement
This project is an extension of the iBRA study7 which was 
designed with patient coapplicants. A patient group will 
be established to review and comment on the results. This 
patient group will input on the design of the future RCT, 
in particular, selection of the most appropriate primary 
outcome measure and timing of assessment.
Setting
All UK breast and plastic surgical centres currently 
performing PPBR using any technique will be invited 
to participate through the UK professional associations 
(Association of Breast Surgery (ABS), British Associa-
tion of Plastic Reconstructive and Aesthetic Surgeons 
(BAPRAS)).
All surgeons currently performing PPBR will be eligible 
to participate in the study but those wishing to start 
performing the technique will be encouraged to follow 
the ABS/BAPARS guidelines regarding mentorship and 
training32 prior to entering patients.
Participants
Inclusion criteria
Consecutive women aged 16 or over who require a 
mastectomy for breast cancer or risk- reduction who elect 
to undergo IBBR are considered technically suitable 
by copyright.
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for PPBR by their surgeon and consent to undergo the 
procedure are eligible to participate in the study. Patients 
undergoing PPBR will be informed that the procedure is 
innovative and that outcome data are limited as part of 
their discussion with the surgical team.
Exclusion criteria
Absolute and relative exclusion criteria will be used to 
reflect current practice and account for the variable 
experience of surgeons performing PPBR across the UK. 
Absolute exclusion criteria will be applied to all patients. 
Relative exclusion criteria can be applied flexibly 
according to the surgeon’s experience with the proce-
dure in conjunction with the patient’s consent following 
discussion that the risk of complications may be increased 
in this setting.
Absolute exclusion criteria
i. Patients assessed as having insufficient soft tissue cov-
erage for PPBR by the operating surgeon.
ii. Patients having revisional or delayed breast 
reconstruction.
iii. Patients unable or unwilling to provide informed 
consent.
Relative exclusion criteria reflect ABS/BAPRAS guide-
lines for mesh- assisted breast reconstruction32 and 
include the following:
i. Current smokers or recent ex- smokers (<6 weeks).
ii. Previous breast/chest wall radiotherapy.
iii. Body mass index (BMI) of greater than 30.
iv. Reconstruction with an implant of more than 600cc.
v. Patients anticipated to require postmastectomy 
radiotherapy.
vi. Poorly controlled diabetes.
Participant identification, screening, and recruitment
All female patients aged 16 or over undergoing mastec-
tomy for breast cancer or risk- reduction who elect to 
undergo immediate IBBR will be screened to inform the 
feasibility of a future trial comparing different approaches 
to IBBR.
Participant screening
Potential participants will be identified from clinics and 
multidisciplinary meetings by the clinical and research 
teams.
A comprehensive screening log will be maintained at 
participating sites of all women who elect to undergo 
immediate IBBR under the care of participating surgeons 
to determine the proportion of the following patients:
1. Patients who are considered technically suitable for 
prepectoral technique by the operating surgeon.
2. For those patients who are considered not suitable for 
PPBR—with reasons for this (eg, relative exclusion cri-
teria: smoker; previous RT, etc, or other reason).
3. For patients considered technically suitable for PPBR, 
the proportion who accept the technique.
4. For those patients accepting PPBR, the proportion 
who consent to study participation.
Patient recruitment
Patients who elect to undergo PPBR will be given a 
patient information sheet explaining the study. They will 
be seen at a follow- up appointment by a member of the 
clinical or research team and asked to sign a consent form 
prior to participating in the study (online supplementary 
appendix 1). Patients will be allocated a study ID number.
Patients will be given a date for surgery as per unit 
protocol and undergo preoperative assessment. They 
will be required to complete baseline patient- reported 
outcome questionnaires (BREAST- Q) and have preoper-
ative photographs as per unit policy prior to surgery.
Study procedures
All patients in whom prepectoral reconstruction with or 
without mesh is planned will be eligible for inclusion in 
the study. All meshes must be licensed for use in the UK 
and have a CE mark. Composite prepectoral reconstruc-
tions using dermal sling and mesh or two different types 
of mesh will be permitted and the details of products used 
will be recorded. Reconstructions using full dermal sling 
coverage will also be included.
Standardisation of surgical technique and procedure fidelity
All patients will undergo a skin or nipple- preserving 
mastectomy followed by an immediate IBBR.
Participating surgeons will undertake the procedure as 
per their standard practice. Mesh choice (biological or 
synthetic and the product used) and implant selection 
(fixed- volume; adjustable implants or tissue expanders) 
will be as per surgeon preference. All patients will be 
planned for a prepectoral reconstruction prior to 
surgery.
The following steps of the PPBR procedure will be 
considered mandatory, prohibited and discretionary 
according to the typology described by Blencowe et al.33
 ► Mandatory—insertion of a tissue expander/adjustable 
implant or fixed- volume implant.
 ► Prohibited—raising the pectoralis muscle.
 ► Discretionary—all other steps of the procedure.
If the surgeon considers that prepectoral reconstruc-
tion is not possible at the time of surgery or modifies the 
planned procedure (eg, inserts tissue expander rather 
than fixed- volume implant), this will be recorded on the 
case report form (CRF) with reasons for the modifica-
tion (eg, thin skin- flaps). Details of the alternative proce-
dure performed (eg, subpectoral reconstruction) will be 
collected. Surgeons will also be encouraged to record any 
learning arising from the case.
Strategies to minimise infection (eg, use of laminar 
flow, cavity irrigation, and glove change) will be as per 
local practice but participating centres will be encour-
aged to adhere to published best practice guidelines32 34 
and use the evidence- based Manchester checklist.35
Use of drains and other concomitant interventions 
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Deviations from planned prepectoral reconstruction
As detailed above, surgeons will be asked to report the 
following via the CRF:
a. Patients in whom PPBR was planned but had to be 
abandoned completely (ie, another form of recon-
struction or no reconstruction performed).
i. Reasons why prepectoral approach was abandoned.
ii. Procedure performed instead.
iii. Any reflections or learning regarding the case.
b. Patients in whom the planned procedure was modified 
(but prepectoral reconstruction still performed).
i. Details of the modification made (eg, insertion of 
tissue expander rather than fixed volume implant).
ii. Reasons for the modification (eg, thin skin flaps).
iii. Any reflections or learning regarding the case.
ouTCoME MEASuRES
Safety and effectiveness outcomes
The primary outcome for the prepectoral safety study 
will be implant loss at 3 months defined as the removal 
of the implant or tissue- expander without replacement 
as a result of a complication. This is consistent with the 
definition used in the iBRA study.7 Secondary safety and 
effectiveness outcomes:
i. Postoperative pain assessed by patient self- report 
using a visual analogue scale at 24 hours, 1 week, 2 
weeks and 3 months.
ii. Complications requiring readmission and/or reoper-
ation at 3 months.
iii. Infection defined as (i) minor—requiring treat-
ment with oral antibiotics, (ii) major requiring ad-
mission for intravenous antibiotics and/or surgical 
debridement.
iv. Quality of life including satisfaction with breasts; 
physical well- being; psychosocial well- being and an-
imation assessed using the validated BREAST- Q36 
questionnaire at 3 and 18 months following surgery.
v. Further surgery for complications or cosmesis at 18 
months
Feasibility outcomes
Surgeon engagement will be used to assess the feasibility 
of using mixed- methods to explore learning and inter-
vention stability in the study. At study entry, the number 
of surgeons completing the surgeon questionnaire; the 
number of surgeons consenting to be contacted for 
interview and the number of surgeons interviewed will 
be compared. For modifications/learning arising from 
complications, the numbers of events (modifications and 
complications) reported will be compared with numbers 
of free- text responses entered; the number of surgeons 
consenting to interview and the actual number inter-
viewed. The content of the free- text responses and inter-
views will also be assessed.
Screening logs will be reviewed to determine the rela-
tive proportions of patients electing to undergo IBBR who 
are (i) considered technically suitable for prepectoral 
reconstruction and (ii) elect to undergo surgery to deter-
mine if a full- scale pragmatic RCT is feasible.
dATA CollECTIon
Clinical data
Demographic, comorbidity and operative data will be 
collected for each participant via a standardised elec-
tronic CRF hosted on REDCap36 (online supplementary 
appendix 2).
Complications and oncological data will be collected at 30 
days and 3 months by clinical or case- note review according 
to local follow- up policies. Details of any additional surgery 
required for complications or cosmesis will be collected at 
18 months by case note review. No additional clinic visits will 
be required for the study. All complications will be defined 
a priori using standardised definitions as per previous 
studies7 37 (online supplementary appendix 3).
Patient-reported outcomes
Participants will be asked to complete the preoperative 
breast reconstruction BREAST- Q questionnaire prior to 
surgery.
Postoperative pain scores will be collected by patient 
self- report using an electronic visual analogue scale at 
24 hours, 1 week, 2 weeks and 3 months following surgery.
Patient satisfaction with breasts, physical well- being, 
psychosocial well- being, satisfaction with implants and 
patient- reported assessment of animation will be assessed at 
3 and 18 months using the validated BREAST- Q question-
naire.38 A reminder will be sent after 1 month if no response 
is received. Patients will be encouraged to complete online 
patient- reported outcome measures (PROMs) but paper 
versions will be made available to patients unable or 
unwilling to use electronic versions.
Shared learning and intervention stability
Best practice and opportunities for shared learning 
among participating surgeons will occur at the following 
points in the study.
i. Study entry.
ii. As a result of procedure modifications or 
complications.
Surgeons electing to participate in the study will be 
sent a surgeon information sheet outlining the proposed 
shared learning study and what participation may involve. 
Surgeons will be able to recruit patients to Pre- BRA 
without contributing to shared learning but full partici-
pation will be encouraged by the steering group.
At each time point, a combination of free- text responses 
on standardised CRFs and focused semistructured qual-
itative interviews will be to explore group learning and 
intervention stability.
Study entry
Phase 1: surgeon questionnaire
Prior to commencing patient recruitment, participating 
surgeons will be asked to complete a surgeon ques-
tionnaire. The questionnaire (online supplementary 
by copyright.
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appendix 4) will explore techniques and products used; 
experience; approaches to concomitant interventions and 
patient selection criteria. The questionnaire will include 
consent to be contacted regarding a brief (20 min) semi-
structured qualitative interview exploring their practice 
in more detail.
Phase 2: semistructured study entry interviews
Sampling and data collection
A purposive sample of surgeons consenting to inter-
view will be selected based on techniques and products 
used; experience; geographical location and differing 
approaches to concomitant interventions and patient 
selection.
Interviews will be organised at a time convenient to the 
participating surgeons. All interviews will be conducted by 
telephone using a semistructured topic guide developed 
based on the literature and clinical expertise to explore 
issues surrounding current practice. All interviews will 
be audiorecorded and transcribed verbatim. Interview 
participants will be asked to give verbal consent to study 
participation and audiorecording prior to commencing 
the interview. The topic guide will be modified iteratively 
as the study progresses to allow new themes to emerge. 
Sampling, data collection and analysis will be conducted 
concurrently and iteratively until data saturation is 
achieved and no new themes emerge from the data. As 
a result of procedure modifications and learning from 
complications.
Phase 1: case report forms
Surgeons will be asked to report (yes/no) whether (i) a 
modification to the planned procedure was made at the 
time of the operation and (ii) any learning (eg, changes 
to future surgical technique) occurred as a result of a 
complication at 3 months. If modifications or learning as 
a result of complications are reported, surgeons will be 
asked to provide details in a free- text response box on 
the electronic CRF and to indicate whether they would be 
willing to be contacted to participate in a brief telephone 
interview to explore this in more detail.
Phase 2: semistructured surgeon modification/complication 
interviews
Sampling and data collection
Surgeons providing consent will be contacted to arrange 
a brief semistructured qualitative interview. Interviews will 
be conducted as per study entry interviews outlined above 
but will focus specifically on the modification/learning 
arising from the complication including details, rationale 
and outcome.
The feasibility of this approach is unknown so initially, 
it is planned that all surgeons reporting procedure modi-
fications/learning from complications and providing 
consent will be interviewed. As the study progresses, 
depending on the number and content of the CRF 
reports, all consenting surgeons may continue to be 
interviewed or, it may be necessary to purposively sample 
consenting surgeons based on the details of the modifi-
cation/learning reported in the CRF to explore new and 
emerging themes and allow the details of the modifica-
tions to be explored. Data collection will continue until 
no new learning or modifications emerge from the data.
data analysis and sample size
Prepectoral safety and effectiveness
Sample size
A single- arm two- stage design will be used to assess the 
safety of PPBR based on the primary outcome of implant 
loss rate at 3 months. It is expected that the implant loss 
rate will be 9% or lower based on findings from the recent 
iBRA study;7 15% or greater will be deemed unacceptably 
high.
A sample size of 310 patients would result in a two- 
sided 95.0% CI for a single proportion, assumed to be 
0.10, with a width equal to 0.070. Allowing for a 10% 
loss to follow- up at 3 months at least 341 patients will be 
recruited to inform a future trial with implant loss as the 
primary outcome.
Based on data from the iBRA study, the number of 
prepectoral reconstructions performed at each site is 
likely to be small (4–40 per year).7 We will therefore aim 
to recruit from between 20 and 30 sites over a period of 
12 months.
Statistical analysis
Simple summary statistics will be calculated to describe 
demographic, procedure, process and outcome data. 
Categorical data will be summarised by counts and 
percentages and continuous data by median, IQR and 
range.
We will establish the proportion and 95% CIs of patients 
experiencing implant loss and other key safety outcomes 
(readmission for complications, reoperation and infec-
tion) at 3 months and compare these with findings with 
those reported in the iBRA study.7
An exploratory risk factor analysis will be conducted to 
explore the impact of type of mesh and known risk factors 
for complications including smoking; BMI and radio-
therapy if sufficient numbers of patients are recruited to 
the study.
Planned interim analysis
A planned interim analysis will be performed when 155 
patients have been recruited to the study and followed- up 
for a minimum of 3 months. The report will be reviewed 
by the study steering group and the results will be made 
available to the study sponsor.
If the overall implant loss rate at 3 months following 
surgery is 15% or more, the study will be stopped.
Shared learning and intervention stability feasibility study
Analysis of the free- text responses will be an ongoing and 
iterative process commencing soon after the study begins 
and will inform sampling for the semistructured interview 
phase of the study. Text will be assigned codes and analysed 
by copyright.
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using the constant comparative technique of grounded 
theory.39 A combination of thematic and content analysis 
will be used to identify common themes.40 41 These will 
inform the topic guide for the interviews and the feed-
back provided to study participants.
Sampling, data collection and analysis will be under-
taken concurrently and iteratively until no new themes 
emerge from the data.
dissemination of best practice and shared learning
The learning and modifications emerging from the 
CRFs and interviews will be consolidated and reviewed 
at regular intervals by the study team. Any common 
themes will be shared with participating surgeons using 
a combination of methods. These will include a ‘tips and 
tricks’ section on the study website; e- mail updates; study 
newsletters and potentially social media channels (eg, 
‘You Tube’). The acceptability and value of the different 
approaches to sharing learning will be discussed with 
individual surgeons at interview and the wider steering 
group. Metrics such as number of views/hits for online/
social media resources will be used to provide additional 
information regarding engagement if appropriate.
design of the main study
If PPBR is considered safe and data from the screening 
logs suggests sufficient numbers of PPBR are being 
performed at participating centres, a consensus meeting 
with key participating surgeons, steering group members, 
patients and methodologists will be held to agree the 
final design for a large- scale pragmatic RCT comparing 
prepectoral and subpectoral IBBR.
dISSEMInATIon
Results will be analysed and presented at national and 
international meetings and published in peer- reviewed 
journals. Findings will be fed back to the surgical commu-
nity to promote engagement and recruitment to a future 
RCT.
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